{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.gray-baby-syndrome","code":"thing-q374186","url":"https://ver.cy/models/thing/q374186/","name":"gray baby syndrome","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Information and virtual systems","entryKind":"thing","plane":"INF","domain":["INF.MED"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Gray baby syndrome is a potentially fatal chloramphenicol toxicity syndrome, classically affecting neonates with immature drug metabolism and clearance, characterized by abdominal distension, gray or cyanotic skin discoloration, and cardiovascular collapse.","purpose":"Enable an AI agent to recognise suspected gray baby syndrome, assess exposure and clinical deterioration, and support timely clinician-led escalation while preserving diagnostic uncertainty.","scope":{"in":["Chloramphenicol exposure and its temporal relationship to suspected toxicity","Developmental and physiological factors affecting drug accumulation","Clinical manifestations, deterioration and recovery","Diagnostic evidence, competing explanations and attribution confidence","Syndrome-specific escalation, monitoring and adverse-reaction documentation"],"out":["The infant's complete longitudinal health record","General chloramphenicol chemistry, manufacture and antimicrobial prescribing","The infection for which chloramphenicol was administered","Other chloramphenicol adverse effects without this syndrome","General neonatal shock protocols and the complete intensive-care encounter"],"boundaries":[]},"distinguishingFeatures":["Establish a plausible chloramphenicol exposure before attributing gray discoloration or circulatory deterioration to this syndrome.","Assess the combination and chronology of abdominal distension, pallid cyanosis, respiratory irregularity and circulatory collapse; these are reported manifestations rather than a validated mandatory checklist. [DailyMed labeling](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aed29594-211d-49ef-813f-131975a8d0e3)","Distinguish elevated chloramphenicol concentrations from the clinical syndrome: a neonatal study reported elevated concentrations in some infants without toxicity. [Primary neonatal study](https://pubmed.ncbi.nlm.nih.gov/6416440/)","Record whether sepsis, cardiac disease, respiratory disease or dyshemoglobinemia better explains the presentation, and allow concurrent causes.","Distinguish this acute toxic presentation from isolated hematological adverse effects attributed to chloramphenicol."],"structure":{"bundles":[{"id":"syndrome-identity-and-boundaries","name":"Syndrome identity and boundaries","description":"Defines what constitutes the chloramphenicol-associated syndrome and how its identity is represented.","layers":[{"id":"clinical-concept","name":"Clinical concept","description":"Establishes the syndrome's exposure-dependent meaning.","findings":[{"id":"case-definition-basis","name":"Case definition basis","description":"Record the definition used, its issuing source and whether it is descriptive or formally validated.","questions":[{"text":"What exposure and clinical evidence does the cited definition require for gray baby syndrome?","id":"case-definition-basis-q01","kind":"definition"},{"text":"Does the definition specify neonatal age limits, and how are reports outside those limits handled?","id":"case-definition-basis-q02","kind":"boundary"}]}]},{"id":"diagnosis-and-coding","name":"Diagnosis and coding","description":"Separates syndrome identity from clinical assertions and administrative coding.","findings":[{"id":"versioned-diagnostic-assertion","name":"Versioned diagnostic assertion","description":"Attach assessor, date, confidence and verified terminology metadata to each diagnostic assertion.","questions":[{"text":"Who attributed the presentation to gray baby syndrome, using which evidence and assessment method?","id":"versioned-diagnostic-assertion-q01","kind":"provenance"},{"text":"Which verified ICD or SNOMED release represents this syndrome, and does the mapping denote the syndrome itself or a broader drug-related event?","id":"versioned-diagnostic-assertion-q02","kind":"boundary"}]}]}]},{"id":"exposure-and-accumulation","name":"Exposure and accumulation","description":"Reconstructs chloramphenicol exposure and factors relevant to excessive concentrations.","layers":[{"id":"administration-history","name":"Administration history","description":"Reconciles prescribed, prepared and administered exposure.","findings":[{"id":"reconstructed-drug-exposure","name":"Reconstructed drug exposure","description":"Record formulation, route, actual doses, intervals, weight basis and evidence for any indirect exposure.","questions":[{"text":"What chloramphenicol formulation and amounts were actually administered, by which route and at what times?","id":"reconstructed-drug-exposure-q01","kind":"measurement"},{"text":"Does the exposure history come from administration records, caregiver reports or documented maternal treatment?","id":"reconstructed-drug-exposure-q02","kind":"provenance"}]}]},{"id":"clearance-context","name":"Clearance context","description":"Places measured concentrations within developmental and organ-function context.","findings":[{"id":"accumulation-evidence","name":"Accumulation evidence","description":"Retain age, renal and hepatic observations, serial drug measurements and sampling context without imposing an unverified toxic threshold.","questions":[{"text":"What developmental age and renal or hepatic findings are relevant to interpreting this infant's exposure?","id":"accumulation-evidence-q01","kind":"measurement"},{"text":"When were concentrations collected relative to dosing, and what evidence supports accumulation rather than an isolated high sample?","id":"accumulation-evidence-q02","kind":"measurement"}]}]}]},{"id":"presentation-and-differential","name":"Presentation and differential","description":"Organises observed manifestations and evaluates competing or concurrent explanations.","layers":[{"id":"manifestation-timeline","name":"Manifestation timeline","description":"Records the onset and sequence of gastrointestinal, colour, respiratory and circulatory changes.","findings":[{"id":"observed-clinical-pattern","name":"Observed clinical pattern","description":"Distinguish observed, absent, unassessed and retrospectively reported manifestations.","questions":[{"text":"Which manifestations were observed, and when did each begin relative to chloramphenicol exposure?","id":"observed-clinical-pattern-q01","kind":"measurement"},{"text":"Which findings were assessed and absent, and which were never assessed?","id":"observed-clinical-pattern-q02","kind":"provenance"}]}]},{"id":"competing-causes","name":"Competing causes","description":"Maintains alternative explanations alongside drug-toxicity attribution.","findings":[{"id":"differential-evidence","name":"Differential evidence","description":"Record evidence for infection-related shock, cardiopulmonary disease, dyshemoglobinemia and other relevant toxic exposures.","questions":[{"text":"What evidence supports or weakens each alternative explanation for the infant's colour change and deterioration?","id":"differential-evidence-q01","kind":"boundary"},{"text":"Could the treated infection or another condition coexist with chloramphenicol toxicity?","id":"differential-evidence-q02","kind":"boundary"}]}]}]},{"id":"severity-and-urgent-response","name":"Severity and urgent response","description":"Connects current physiological compromise with documented clinical escalation.","layers":[{"id":"physiological-severity","name":"Physiological severity","description":"Tracks circulatory and respiratory compromise without inventing a syndrome-specific severity score.","findings":[{"id":"deterioration-and-support","name":"Deterioration and support","description":"Record serial observations together with respiratory and circulatory support already in use.","questions":[{"text":"What current observations demonstrate respiratory compromise or impaired circulation, and how are they changing?","id":"deterioration-and-support-q01","kind":"measurement"},{"text":"Which findings meet the applicable neonatal escalation protocol, and has the responsible clinician been alerted?","id":"deterioration-and-support-q02","kind":"action"}]}]},{"id":"exposure-cessation-and-care","name":"Exposure cessation and care","description":"Records decisions about further exposure and specialist-led management.","findings":[{"id":"documented-response-decisions","name":"Documented response decisions","description":"Capture the last dose, discontinuation decision, urgent clinical review and links to treatment plans.","questions":[{"text":"Has chloramphenicol been discontinued, when was the last dose, and who documented the decision?","id":"documented-response-decisions-q01","kind":"action"},{"text":"What neonatal or toxicology guidance supports the selected monitoring and treatment, including any proposed enhanced drug elimination?","id":"documented-response-decisions-q02","kind":"provenance"}]}]}]},{"id":"resolution-and-case-learning","name":"Resolution and case learning","description":"Documents recovery, residual uncertainty and evidence suitable for adverse-reaction review.","layers":[{"id":"response-and-outcome","name":"Response and outcome","description":"Follows manifestations and concentrations after exposure ends.","findings":[{"id":"dechallenge-and-resolution","name":"Dechallenge and resolution","description":"Record improvement after withdrawal alongside simultaneous interventions and unresolved abnormalities.","questions":[{"text":"How did manifestations and measured concentrations change after the last dose?","id":"dechallenge-and-resolution-q01","kind":"measurement"},{"text":"What evidence supports resolution, and which concurrent treatments limit attribution of improvement to drug withdrawal?","id":"dechallenge-and-resolution-q02","kind":"boundary"}]}]},{"id":"adverse-reaction-record","name":"Adverse-reaction record","description":"Preserves a reviewable account for pharmacovigilance and future medication decisions.","findings":[{"id":"traceable-case-summary","name":"Traceable case summary","description":"Assemble exposure, phenotype, assessment and outcome without automatically classifying toxicity as allergy.","questions":[{"text":"Which source records substantiate the suspected reaction, and which uncertainties must accompany any report?","id":"traceable-case-summary-q01","kind":"provenance"},{"text":"What clinician-approved medication alert or adverse-reaction documentation should follow this assessment?","id":"traceable-case-summary-q02","kind":"action"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of gray baby syndrome this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-standards-and-regulation","name":"Standards and regulation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these standards and regulation hold for the sense of gray baby syndrome this model covers, and on what evidence?","id":"evidence-standards-and-regulation-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of gray baby syndrome this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-measurements","name":"Typical measurements","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these typical measurements hold for the sense of gray baby syndrome this model covers, and on what evidence?","id":"evidence-measurements-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of gray baby syndrome this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of gray baby syndrome this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Explain gray baby syndrome and its link to chloramphenicol from reliable medical sources.","Point parents and carers to a doctor or emergency service when a newborn seems unwell.","Flag chloramphenicol in a newborn's medication record for clinician review."],"mustNot":["Diagnose gray baby syndrome in a particular infant.","Recommend, adjust or stop any medicine dose for a newborn or a pregnant or breastfeeding person.","Suggest that a sick newborn can wait for home care instead of urgent medical attention.","Blame parents or named clinicians for a case without evidence."],"requiresHuman":["Any treatment decision for an infant suspected of drug toxicity."]},"ethics":{"considerations":["Newborns cannot speak for themselves; delay or bad advice can cost a life.","Medication errors in neonates must be reported honestly so others can learn from them."],"affectedParties":["Newborn infants","Parents and carers","Neonatal clinicians"]},"owners":{"steward":"Nobody owns the condition; the treating clinician answers for each patient and medicines regulators for drug safety.","roles":[],"masterSystems":[]},"relations":[{"target":"Q387175","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.gray-baby-syndrome","Wikidata: Q374186 (https://www.wikidata.org/wiki/Q374186)"]},"properties":{"applicability":"not-applicable","items":["Exposure provenance: Links to medication administration, dispensing or maternal exposure evidence; documented, reported, inferred or unknown","Developmental age at exposure: Gestational age at birth in weeks and days; postnatal age in days; postmenstrual age in weeks and days","Administered chloramphenicol exposure: mg per administration, mg/kg per administration, interval in hours, route, formulation and timestamp","Chloramphenicol concentration: mg/L or equivalent micrograms/mL, with specimen, analyte, collection time and elapsed time since dose","Clinical trajectory: Suspected evolving toxicity, deteriorating, stabilising, recovering, resolved or unknown; descriptive states rather than validated stages","Circulatory and respiratory observations: Blood pressure in mmHg, heart and respiratory rates per minute, oxygen saturation in percent, with timestamps and support context","Attribution status: Suspected, clinician-supported, disputed, excluded or unresolved; assessor and assessment method required","Terminology mapping: Coding system, edition or release, jurisdiction, identifier, label and mapping relationship; unverified when unresolved"]},"recognition":{"applicability":"optional","items":["Gray or blue skin discoloration can raise suspicion in a newborn with documented chloramphenicol exposure, but it is not specific to this syndrome.","Abdominal distension accompanying the discoloration can support suspicion while overlapping with other neonatal illnesses.","A limp appearance and visibly irregular breathing can accompany severe deterioration, but appearance alone cannot establish the diagnosis."]},"capabilities":{"applicability":"required","items":["Assemble a timestamped exposure-to-deterioration timeline.","Flag compatible deterioration after chloramphenicol exposure for urgent clinician review.","Identify missing dose, weight, specimen-timing or competing-diagnosis evidence.","Compare clinical and concentration trends before and after documented interventions.","Prepare a traceable suspected adverse-reaction summary for clinician review.","Link a diagnostic assertion to a verified terminology release while retaining unresolved mappings."]},"hazards":{"applicability":"required","items":["Severe toxicity can progress to cardiovascular collapse and death.","Confusion with sepsis or other causes of neonatal cyanosis can delay recognition of drug toxicity.","Failure to identify chloramphenicol exposure can allow the underlying toxic effect to continue."]},"interfaces":{"applicability":"required","items":["The World Health Organization's ICD-10 category P93 covers reactions and intoxications due to drugs administered to the fetus and newborn, including gray syndrome from chloramphenicol administration."]},"context":{"applicability":"required","items":["Gray baby syndrome is encountered in neonatal medicine and drug safety assessment following chloramphenicol exposure.","The term helps clinicians describe suspected toxicity involving impaired drug clearance and potentially severe circulatory deterioration."]}},"sources":[{"title":"Wikidata item Q374186: gray baby syndrome","url":"https://www.wikidata.org/wiki/Q374186","note":"identity and sense of the item"},{"title":"Wikipedia: Gray baby syndrome","url":"https://en.wikipedia.org/wiki/Gray_baby_syndrome","note":"general description of the item"}],"openQuestions":["Is there a validated contemporary diagnostic definition or severity classification, and which issuing body and version should govern its use?","What exact ICD-10, ICD-11 and SNOMED CT mappings apply across jurisdictions and releases, including distinctions between adverse effects and poisoning?","What contemporary incidence or prevalence estimates exist with explicit population, exposure denominator, location and observation year?","How should neonatal, older-infant and older-patient gray syndrome reports be bounded within this registry entry without creating unsupported separate concepts?","What evidence supports concentration interpretation and enhanced elimination interventions in affected infants, and how dependent is that evidence on historical case reports?"],"resources":{"spec":"/models/things/publications/thing-q374186/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q374186/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:05:31Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"not-applicable","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:30+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass","interaction.properties":"Plane INF: no invented physical properties."},"score":1.0}}